Entero Therapeutics Reports Financial Obligation Event

TL;DR

Entero Therapeutics just dropped an 8-K about a financial obligation acceleration - watch this space.

AI Summary

On November 21, 2024, Entero Therapeutics, Inc. reported a triggering event related to accelerating or increasing a direct financial obligation. The company, formerly known as First Wave BioPharma, Inc., filed an 8-K to disclose this information, which is a standard regulatory filing.

Why It Matters

This filing indicates a potential acceleration or increase in the company's financial obligations, which could impact its liquidity and future financial health.

Risk Assessment

Risk Level: medium — Filings related to accelerating financial obligations can signal potential financial distress or increased leverage for the company.

Key Players & Entities

• Entero Therapeutics, Inc. (company) — Registrant
• November 21, 2024 (date) — Date of earliest event reported
• First Wave BioPharma, Inc. (company) — Former company name
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Marke
• $7.4 m — the Credit Agreement were approximately $7.4 million, including outstanding principal,

Filing Documents

• tm2429671d1_8k.htm (8-K) — 31KB
• 0001104659-24-123742.txt ( ) — 202KB
• fwbi-20241121.xsd (EX-101.SCH) — 3KB
• fwbi-20241121_lab.xml (EX-101.LAB) — 33KB
• fwbi-20241121_pre.xml (EX-101.PRE) — 22KB
• tm2429671d1_8k_htm.xml (XML) — 4KB

04 Triggering Events That Accelerate

Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. As previously disclosed in Entero Therapeutics, Inc.'s ("we", "us", "our", or the "Company") Current Report on Form 8-K filed with the SEC on March 14, 2024, the Company acquired ImmunogenX, Inc. in a merger transaction, the terms of which included, among other things, the Company's wholly owned subsidiary, ImmunogenX, LLC ("ImmunogenX"), assuming the debt of ImmunogenX, Inc. On November 21, 2024, ImmunogenX received a Notice of Default and Demand for Payment (the "Notice") relating to that certain Credit Agreement, dated as of October 3, 2022 (as amended, modified, supplemented or restated from time to time, the "Credit Agreement") by and among Mattress Liquidators, Inc. ("Lender") and ImmunogenX, Inc. The Notice informed ImmunogenX that one or more events of default under the Credit Agreement ("Events of Default") were existing and continuing. Such outstanding Events of Default include (1) ImmunogenX failing to provide Lender complete and accurate financial statements of ImmunogenX for the period ended March 31, 2024, June 30, 2024, and September 30, 2024 (the "IMGX Financial Statements"), (2) ImmunogenX's cessation of operations constituting a material change in the general nature of ImmunogenX's business and a Material Adverse Effect (as defined in the Credit Agreement), and (3) failure to provide notice of ImmunogenX's cessation of operations. The Company does not agree that any Event of Default exists or is continuing as it relates to the IMGX Financial Statements. In addition to being publicly available, the Company has provided Lender with copies of its Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, June 30, 2024, and September 30, 2024 (the "Quarterly Reports"). As stated in the Quarterly Reports, the Company prepares its financial statements on a consolidated basis and the requested financi

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. November 27, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR